Aprea Therapeutics, Inc. (APRE) Free cash flow 2018–2024
Aprea Therapeutics, Inc. (APRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$13.6MFY2024 · since FY2018: -$15.3M → -$13.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$13.6M | -10.6% |
| FY2023 | -$12.3M | — |
| FY2020 | -$41.8M | -56.4% |
| FY2019 | -$26.7M | -75.3% |
| FY2018 | -$15.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice